Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2019 Sep 9;17(4):eAO4742.
doi: 10.31744/einstein_journal/2019AO4742.

Evaluation of hydroxyurea genotoxicity in patients with sickle cell disease

[Article in English, Portuguese]
Affiliations
Clinical Trial

Evaluation of hydroxyurea genotoxicity in patients with sickle cell disease

[Article in English, Portuguese]
Emanuel Almeida Moreira de Oliveira et al. Einstein (Sao Paulo). .

Abstract

Objective: To evaluate the induction of DNA damage in peripheral blood mononuclear cells of patients with sickle cell disease, SS and SC genotypes, treated with hydroxyurea.

Methods: The study subjects were divided into two groups: one group of 22 patients with sickle cell disease, SS and SC genotypes, treated with hydroxyurea, and a Control Group composed of 24 patients with sickle cell disease who were not treated with hydroxyurea. Peripheral blood samples were submitted to peripheral blood mononuclear cell isolation to assess genotoxicity by the cytokinesis-block micronucleus cytome assay, in which DNA damage biomarkers - micronuclei, nucleoplasmic bridges and nuclear buds - were counted.

Results: Patients with sickle cell disease treated with hydroxyurea had a mean age of 25.4 years, whereas patients with sickle cell disease not treated with hydroxyurea had a mean age of 17.6 years. The mean dose of hydroxyurea used by the patients was 12.8mg/kg/day, for a mean period of 44 months. The mean micronucleus frequency per 1,000 cells of 8.591±1.568 was observed in the Hydroxyurea Group and 10.040±1.003 in the Control Group. The mean frequency of nucleoplasmic bridges per 1,000 cells and nuclear buds per 1,000 cells for the hydroxyurea and Control Groups were 0.4545±0.1707 versus 0.5833±0.2078, and 0.8182±0.2430 versus 0.9583±0.1853, respectively. There was no statistically significant difference between groups.

Conclusion: In the study population, patients with sickle cell disease treated with the standard dose of hydroxyurea treatment did not show evidence of DNA damage induction.

Objetivo: Avaliar o efeito da indução de danos ao DNA em células monocelulares do sangue periférico de pacientes com doença falciforme, genótipos SS e SC, tratados com hidroxiureia.

Métodos: Os sujeitos da pesquisa foram divididos em dois grupos: um de 22 pacientes com doença falciforme genótipos SS e SC tratados com hidroxiureia, e o outro controle, composto por 24 pacientes com doença falciforme que não eram tratados com o fármaco. As amostras de sangue periférico foram submetidas ao isolamento de células mononucleares do sangue periférico para avaliação da genotoxicidade pelo ensaio de micronúcleo citoma com bloqueio da citocinese, tendo sido quantificados os biomarcadores de danos ao DNA – micronúcleos, pontes nucleoplasmáticas e brotamento nuclear.

Resultados: Os pacientes com doença falciforme tratados com hidroxiureia apresentaram média de idade de 25,4 anos, enquanto aqueles com doença falciforme não tratados com hidroxiureia tiveram média de idade de 17,6 anos. A dose média de hidroxiureia utilizada pelos pacientes foi de 12,8mg/kg/dia, por período médio de 44 meses. A frequência média de micronúcleos por 1.000 células de 8,591±1,568 foi observada no Grupo Hidroxiureia e de 10,040±1,003 no Grupo Controle. Adicionalmente, a frequência média de pontes nucleoplasmáticas por 1.000 células e brotamento nuclear por 1.000 células para o Grupo Hidroxiureia e Controle foi de 0,4545±0,1707 versus 0,5833±0,2078, e de 0,8182±0,2430 versus 0,9583±0,1853, respectivamente. Não houve diferença estatisticamente significativa entre os grupos.

Conclusão: Na população estudada de pacientes com doença falciforme com tratamento em dose padrão de hidroxiureia, não houve evidência de indução de danos ao DNA.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest:

none.

Figures

Figure 1
Figure 1. Evaluation of the genotoxicity effect by means of cytokinesis block micronucleus cytome assay in peripheral blood mononuclear cells of patients with sickle cell disease SS or SC, treated with hydroxyurea (HU Group; n=22) and not treated with this drug (Control Group; n=24). Mean frequency of micronuclei (MN): (A) nucleoplasmic bridges (NPBs); (B) nuclear buds (NBUDs); (C) and Nuclear Division Index (NDI); (D) in binuclear cells (BN). There was no significant difference between the groups studied (p>0.05), according to the paired t test
Figura 1
Figura 1. Avaliação do efeito de genotoxicidade por meio do ensaio de micronúcleo citoma com bloqueio da citocinese em células mononucleares de sangue periférico de pacientes com doença falciforme SS ou SC tratados com hidroxiureia (Grupo HU; n=22) e não tratados com esse fármaco (Grupo Controle; n=24). Frequência média de micronúcleos (MN): (A) pontes nucleoplasmáticas (NPBs); (B) brotos nucleares (NBUDs); (C) e Índice de Divisão Nuclear (IDN); (D) em células binucleadas (BN). Não houve diferença significativa entre os grupos estudados (p>0,05) de acordo com o teste t pareado

Similar articles

Cited by

References

    1. 1. Lovett PB, Sule HP, Lopez BL. Sickle cell disease in the emergency department. Emerg Med Clin North Am. 2014;32(3):629-47. Review. - PubMed
    2. Lovett PB, Sule HP, Lopez BL. Sickle cell disease in the emergency department. Emerg Med Clin North Am. 2014;32(3):629–647. Review. - PubMed
    1. 2. Venkataraman A, Adams RJ. Neurologic complications of sickle cell disease. Handb Clin Neurol. 2014;120:1015-25. Review. - PubMed
    2. Venkataraman A, Adams RJ. Neurologic complications of sickle cell disease. Handb Clin Neurol. 2014;120:1015–1025. Review. - PubMed
    1. 3. Nevitt SJ, Jones AP, Howard J. Hydroxyurea (hydroxycarbamide) for sickle cell disease. Cochrane Database Syst Rev. 2017;4:CD002202. Review. - PMC - PubMed
    2. Nevitt SJ, Jones AP, Howard J. Hydroxyurea (hydroxycarbamide) for sickle cell disease. Cochrane Database Syst Rev. 2017;4:CD002202. Review. - PMC - PubMed
    1. 4. Ware RE. How I use hydroxyurea to treat young patients with sickle cell anemia. Blood. 2010;115(26):5300-11. Review. - PMC - PubMed
    2. Ware RE. How I use hydroxyurea to treat young patients with sickle cell anemia. Blood. 2010;115(26):5300–5311. Review. - PMC - PubMed
    1. 5. Strouse JJ, Lanzkron S, Beach MC, Haywood C, Park H, Witkop C, et al. Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children. Pediatrics. 2008;122(6):1332-42. Review. - PubMed
    2. Strouse JJ, Lanzkron S, Beach MC, Haywood C, Park H, Witkop C, et al. Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children. Pediatrics. 2008;122(6):1332–1342. Review. - PubMed

Publication types

MeSH terms

Substances